Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.

Fremanezumab treatment reduced migraine-associated disability compared with placebo for participants in both age groups and of both sexes, as measured by MIDAS scores, although the difference did not reach statistical significance for participants 18 to 45 years of age receiving quarterly fremanezumab.

also in 111,027 other papers